HHS publishes its six-peptide compounding notice: conditions, comments, and what it means in Canada
News from Oct 30, 2026. Updated October 29, 2026. Based on the Federal Register public inspection copy of the notice and the HHS policy text. News, not advice.
a Federal Register notice from the US Department of Health and Human Services, scheduled for publication on Oct 30, 2026, sets out an enforcement discretion policy for six peptides.
- HHS says it "does not intend to take enforcement action" against a state-licensed pharmacy, federal facility or licensed physician compounding with a listed peptide, under stated conditions.
- The notice says the policy is "not binding on HHS or the public" and that comments are open for two weeks after publication.
What the notice says
| Question | What the documents say |
|---|---|
| Who | HHS, Office of the Secretary, Docket HHS-OASH-2026-0496 |
| Peptides (Appendix A) | BPC-157, epitalon, KPV, MOTS-c, semax, TB-500 |
| What kind of action | A notice of availability of an enforcement discretion policy, not a final rule |
| Who is covered | State-licensed pharmacies, federal facilities and licensed physicians compounding under section 503A |
| Conditions (summary) | Patient-specific prescription, one active ingredient per product, ingredient from an FDA-registered manufacturer with a certificate of analysis, adverse event and quality reporting to MedWatch and states, label reading "This is a compounded drug product. Not for resale." |
| Route limits (Appendix B) | Listed per peptide, for example semax as an intranasal free base, KPV topical and oral, TB-500 and MOTS-c by injection |
| Comments | Until two weeks after Federal Register publication, through regulations.gov |
| How long | A peptide stays under the policy until FDA addresses it in a final rule on the 503A bulks list |
Background
- On Oct 28, 2026 HHS said it would temporarily allow compounding of these six peptides by prescription, see the Oct 28 report.
- In July 2026 an FDA advisory panel recommended the six for the 503A bulks list, see the vote scorecard.
Still unclear
- The final published text and exact comment deadline. I read the public inspection copy, which was scheduled for Oct 30, and have not confirmed the final version.
- When FDA will finish the rulemaking that ends the interim policy.
- Becker's reports that the Alliance for Safe Biologic Medicines, a group of patient and physician organizations, sent HHS an Oct 26 letter asking it to hold the policy. That is one secondary source and I have not seen the letter.
- BakerHostetler, a law firm, says the policy does not cover 503B outsourcing facilities or products sold as research chemicals or dietary supplements. That is one law firm's reading.
What it means in Canada
The notice is about US pharmacies and US federal enforcement. A foreign decision does not change Canadian rules unless Health Canada acted, and I have found no Health Canada action in response. The Canadian position I can verify is Health Canada's April 2026 advisory: peptides are generally regulated as prescription drugs, and a research use only label does not make a product legal, see what the advisory says and Health Canada versus FDA.
How to read news like this: how to read peptide news.
Ready to order?
Enter the code at checkout. If you copied it, just paste it in the Promo code box in the order summary, then press Apply. It does not apply by itself. Confirm the discount line before you pay.
Common questions
Which peptides does the HHS notice cover?
BPC-157, epitalon, KPV, MOTS-c, semax and TB-500, per Appendix A of the HHS policy.
Is this an approval?
No. It is an enforcement discretion policy. The notice says it is not binding on HHS or the public.
When do comments close?
Two weeks after Federal Register publication, which was scheduled for Oct 30, 2026. I have not confirmed the final publication date.
Does it change the rules in Canada?
No. It concerns US pharmacies. Health Canada's April 2026 advisory is the Canadian rule I can verify.
Sources
- Federal Register public inspection: HHS, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (scheduled Oct 30, 2026)
- HHS: 503A peptide enforcement discretion policy, Appendix A and B (PDF)
- BakerHostetler: HHS issues enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances (Oct 28, 2026, law firm alert)
- Becker's Hospital Review: HHS allows compounding of 6 unapproved peptides (Oct 28, 2026)
- Health Canada: think twice before injecting peptides bought online
Summarised in my own words. Read the originals for the full detail.